September/October 2010, Vol 3, No 5
The infuriating reality of healthcare is that it must be run in a systematic way, and that one aspect of that system must be policy (the other 2 are clinical and business). And of course, policy means that politicians ultimately weigh in and “decide” things fundamentally outside their areas of expertise. Not known for consistent fiscal brilliance, their stamp on healthcare often means that much of the downstream effects of legislation consist of crisis management aimed at containing the clinical or economic ruin the legislation overlooked during the planning phase.
Research on health communications has gained prominence over the past few years.1 In the United States, healthcare consumers are expected to read and act on communications from various sources, including federal and state governments, the Social Security Administration, private insurance plans, managed care organizations, and voluntary health agencies. Written materials are not the only means of acquiring health information, but they are the most widely used tool for disseminating crucial information.
Medicare Part D Education Materials Must Address Recipients' Literacy Level
In the United States, brand-name price inflation for prescription drugs has outpaced overall prescription drug price inflation.1,2 Although certain forces in the market may account for this situation, this study focused on the lack of adequate and accurate information that is needed in the market to optimize utilization of prescription drugs and mediate costs.
Aligning Stakeholders Can Maximize the Opportunity for Cost-Savings on Drugs
FDA’s Approval Process Borne Out by a Large Study: But Communicating Generics’ Safety and Efficacy to the Public Leaves Much to Be Desired
In September 2010, the US Food and Drug Administration (FDA) conducted a webinar for the media to review the basic information concerning FDA’s approval of generic drugs1 in an attempt to promote the public’s understanding of generics and dispel common misconceptions about this growing branch of pharmaceutical products that are surrounded by a veil of confusion and controversy.
John T. Lynch, MPH, Catherine E. Cooke, PharmD, BCPS, PAHM, Jonathan Rosen, MD, Sanjay Gandhi, PhD, Michael F. Bullano, PharmD
The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines and 2004 update stress the importance of achieving low-density lipoprotein cholesterol (LDL-C) goals in patients with dyslipidemia.1,2 Patients at higher coronary heart disease (CHD) risk have lower LDL-C goals and require more aggressive lipid-modifying therapy to achieve these goals than patients at lower CHD risk.
Appropriate Medication Selection Key to Cost-Effective Therapy, Patient Adherence
The Patient Protection and Affordable Care Act (PPACA)1 and the Health Care and Education Reconciliation Act2 of 2010 may be the first steps in the process of federal healthcare reform, but many of the provisions of the PPACA represent further movement on a path that has been laid out over the past decade by policymakers in the public and the private sectors—the historical aim of increasing value in healthcare.
Results 1 - 6 of 6